|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Capitanio U and Montorsi F: Renal cancer.
Lancet. 387:894–906. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Motzer RJ, Jonasch E, Agarwal N, Bhayani
S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman
M, et al: Kidney cancer, version 2.2017, NCCN clinical practice
guidelines in oncology. J Natl Compr Canc Netw. 15:804–834. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang JC and Childs R: Immunotherapy for
renal cell cancer. J Clin Oncol. 24:5576–5583. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Simonaggio A, Elaidi R, Fournier L, Fabre
E, Ferrari V, Borchiellini D, Thouvenin J, Barthelemy P, Thibault
C, Tartour E, et al: Variation in neutrophil to lymphocyte ratio
(NLR) as predictor of outcomes in metastatic renal cell carcinoma
(mRCC) and non-small cell lung cancer (mNSCLC) patients treated
with nivolumab. Cancer Immunol Immunother. 69:2513–2522. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shang B, Guo L, Shen R, Cao C, Xie R,
Jiang W, Wen L, Bi X, Shi H, Zheng S, et al: Prognostic
significance of NLR about NETosis and lymphocytes perturbations in
localized renal cell carcinoma with tumor thrombus. Front Oncol.
11:7715452021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Boissier R, Campagna J, Branger N,
Karsenty G and Lechevallier E: The prognostic value of the
neutrophil-lymphocyte ratio in renal oncology: A review. Urol
Oncol. 35:135–141. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hu H, Yao X, Xie X, Wu X, Zheng C, Xia W
and Ma S: Prognostic value of preoperative NLR, dNLR, PLR and CRP
in surgical renal cell carcinoma patients. World J Urol.
35:261–270. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rao Z, Zhu Y, Yang P, Chen Z, Xia Y, Qiao
C, Liu W, Deng H, Li J, Ning P and Wang Z: Pyroptosis in
inflammatory diseases and cancer. Theranostics. 12:4310–4329. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee HM, Lee HJ and Chang JE: Inflammatory
cytokine: An attractive target for cancer treatment. Biomedicines.
10:21162022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sharma N and Jha S: NLR-regulated pathways
in cancer: Opportunities and obstacles for therapeutic
interventions. Cell Mol Life Sci. 73:1741–1764. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li Y, Jia H, Yu W, Xu Y, Li X, Li Q and
Cai S: Nomograms for predicting prognostic value of inflammatory
biomarkers in colorectal cancer patients after radical resection.
Int J Cancer. 139:220–231. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li MX, Liu XM, Zhang XF, Zhang JF, Wang
WL, Zhu Y, Dong J, Cheng JW, Liu ZW, Ma L and Lv Y: Prognostic role
of neutrophil-to-lymphocyte ratio in colorectal cancer: A
systematic review and meta-analysis. Int J Cancer. 134:2403–2413.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gu X, Gao X, Li X, Qi X, Ma M, Qin S, Yu
H, Sun S, Zhou D and Wang W: Prognostic significance of
neutrophil-to-lymphocyte ratio in prostate cancer: Evidence from
16,266 patients. Sci Rep. 6:220892016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Marchioni M, Primiceri G, Ingrosso M,
Filograna R, Castellan P, De Francesco P and Schips L: The clinical
use of the neutrophil to lymphocyte ratio (NLR) in urothelial
cancer: A systematic review. Clin Genitourin Cancer. 14:473–484.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Saputra HM, Hidayatullah F, Kloping YP,
Renaldo J, Chung E and Hakim L: Prognostic value of
neutrophil-to-lymphocyte ratio (NLR) in penile cancer: A systematic
review and meta-analysis. Ann Med Surg (Lond).
81:1043352022.PubMed/NCBI
|
|
18
|
Stares M, Ding TE, Stratton C, Thomson F,
Baxter M, Cagney H, Cumming K, Swan A, Ross F, Barrie C, et al:
Biomarkers of systemic inflammation predict survival with
first-line immune checkpoint inhibitors in non-small-cell lung
cancer. ESMO Open. 7:1004452022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tokumaru Y, Oshi M, Murthy V, Tian W, Yan
L, Angarita FA, Nagahashi M, Matsuhashi N, Futamura M, Yoshida K,
et al: Low intratumoral genetic neutrophil-to-lymphocyte ratio
(NLR) is associated with favorable tumor immune microenvironment
and with survival in triple negative breast cancer (TNBC). Am J
Cancer Res. 11:5743–5755. 2021.PubMed/NCBI
|
|
20
|
Ouyang H, Xiao B, Huang Y and Wang Z:
Baseline and early changes in the neutrophil-lymphocyte ratio (NLR)
predict survival outcomes in advanced colorectal cancer patients
treated with immunotherapy. Int Immunopharmacol. 123:1107032023.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kobayashi T, Ito K, Kojima T, Maruyama S,
Mukai S, Tsutsumi M, Miki J, Okuno T, Yoshio Y, Matsumoto H, et al:
Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the
efficacy of second-line pembrolizumab treatment in urothelial
cancer regardless of the pre-chemo NLR. Cancer Immunol Immunother.
71:461–471. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mandaliya H, Jones M, Oldmeadow C and
Nordman II: Prognostic biomarkers in stage IV non-small cell lung
cancer (NSCLC): Neutrophil to lymphocyte ratio (NLR), lymphocyte to
monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and
advanced lung cancer inflammation index (ALI). Transl Lung Cancer
Res. 8:886–894. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Grassadonia A, Graziano V, Iezzi L, Vici
P, Barba M, Pizzuti L, Cicero G, Krasniqi E, Mazzotta M, Marinelli
D, et al: Prognostic relevance of neutrophil to lymphocyte ratio
(NLR) in luminal breast cancer: A retrospective analysis in the
neoadjuvant setting. Cells. 10:16852021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hu X, Tian T, Zhang X, Sun Q, Chen Y and
Jiang W: Neutrophil-to-lymphocyte and hypopharyngeal cancer
prognosis: System review and meta-analysis. Head Neck. 45:492–502.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen S, Zhang L, Yan G, Cheng S, Fathy AH,
Yan N and Zhao Y: Neutrophil-to-lymphocyte ratio is a potential
prognostic biomarker in patients with ovarian cancer: A
meta-analysis. Biomed Res Int. 2017:79434672017.PubMed/NCBI
|
|
26
|
Shao Y, Wu B, Jia W, Zhang Z, Chen Q and
Wang D: Prognostic value of pretreatment neutrophil-to-lymphocyte
ratio in renal cell carcinoma: A systematic review and
meta-analysis. BMC Urol. 20:902020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Allenet C, Klein C, Rouget B, Margue G,
Capon G, Alezra E, Blanc P, Estrade V, Bladou F, Robert G and
Bernhard JC: Can pre-operative neutrophil-to-lymphocyte ratio (NLR)
help predict non-metastatic renal carcinoma recurrence after
nephrectomy? (UroCCR-61 study). Cancers (Basel). 14:56922022.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Korkmaz M and Erylmaz MK: Systemic
inflammatory markers predicting the overall survival of patients
using tyrosine kinase inhibitors in the first-line treatment of
metastatic renal cell carcinoma. J Coll Physicians Surg Pak.
33:653–658. 2023.PubMed/NCBI
|
|
29
|
Tucker MD, Brown LC, Chen YW, Kao C,
Hirshman N, Kinsey EN, Ancell KK, Beckermann KE, Davis NB,
McAlister R, et al: Association of baseline
neutrophil-to-eosinophil ratio with response to nivolumab plus
ipilimumab in patients with metastatic renal cell carcinoma.
Biomark Res. 9:802021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cordeiro MD, Ilario EN, Abe DK, Carvalho
PA, Muniz DQB, Sarkis AS, Coelho RF, Guimarães RM, Haddad MV and
Nahas WC: Neutrophil-to-lymphocyte ratio predicts cancer outcome in
locally advanced clear renal cell carcinoma. Clin Genitourin
Cancer. 20:102–106. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Young M, Tapia JC, Szabados B, Jovaisaite
A, Jackson-Spence F, Nally E and Powles T: NLR outperforms low
hemoglobin and high platelet count as predictive and prognostic
biomarker in metastatic renal cell carcinoma treated with immune
checkpoint inhibitors. Clin Genitourin Cancer. 22:1020722024.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Asif A, Chan VWS, Osman FH, Koe JSE, Ng A,
Burton OE, Cartledge J, Kimuli M, Vasudev N, Ralph C, et al: The
prognostic value of neutrophil-to-lymphocyte ratio and
platelet-to-lymphocyte ratio for small renal cell carcinomas after
image-guided cryoablation or radio-frequency ablation. Cancers
(Basel). 15:21872023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Edge SB and Compton CC: The American joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lo CK, Mertz D and Loeb M:
Newcastle-Ottawa Scale: Comparing reviewers' to authors'
assessments. BMC Med Res Methodol. 14:452014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Parmar MK, Torri V and Stewart L:
Extracting summary statistics to perform meta-analyses of the
published literature for survival endpoints. Stat Med.
17:2815–2834. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tierney JF, Stewart LA, Ghersi D, Burdett
S and Sydes MR: Practical methods for incorporating summary
time-to-event data into meta-analysis. Trials. 8:162007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
DerSimonian R and Laird N: Meta-analysis
in clinical trials. Control Clin Trials. 7:177–188. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Guyatt G, Oxman AD, Akl EA, Kunz R, Vist
G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, DeBeer H, et al:
GRADE guidelines: 1. Introduction-GRADE evidence profiles and
summary of findings tables. J Clin Epidemiol. 64:383–394. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Parosanu AI, Baston C, Stanciu IM, Parlog
CF and Nitipir C: Second-line treatment of metastatic renal cell
carcinoma in the era of predictive biomarkers. Diagnostics (Basel).
13:24302023. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Parosanu AI, Pirlog CF, Slavu CO, Stanciu
IM, Cotan HT, Vrabie RC, Popa AM, Olaru M, Iaciu C, Bratu LI, et
al: The prognostic value of neutrophil-to-lymphocyte ratio in
patients with metastatic renal cell carcinoma. Curr Oncol.
30:2457–2464. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nagamoto S, Urakami S, Oka S, Ogawa K,
Kono K, Sakaguchi K, Kinowaki K, Yamada D and Kume H: Impact of the
neutrophil-to-lymphocyte ratio as a surgical prognostic factor in
renal cell carcinoma with inferior-vena-cava tumor thrombus. Asian
J Surg. 46:192–200. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ni J, Wang Y, Zhang H, Wang K, Song W, Luo
M, Che J, Geng J, Xu Y, Yao X, et al: Combination of preoperative
plasma fibrinogen and neutrophil-to-lymphocyte ratio to predict the
prognosis for patients undergoing laparoscopic nephrectomy for
renal cell carcinoma. Am J Cancer Res. 12:3713–3728.
2022.PubMed/NCBI
|
|
43
|
Chaker K, Ouanes Y, Dali KM, Bibi M,
Messaoudi Y, Mosbehi B, Abid K, Sellami A, Ben Rhouma S and Nouira
Y: The prognostic value of preoperative neutrophil-to-lymphocyte
ratio in patients with non-metastatic renal cell carcinoma. Prog
Urol. 32:585–592. 2022.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang J, Ye J, Zhao X, Li X and Ma X:
Prognostic value and model construction of preoperative
inflammatory markers in patients with metastatic renal cell
carcinoma. World J Surg Oncol. 21:2112023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang Z, Qin Y, Chai X, Lu L, Xue P, Lu R,
Miao C, Ma H, Hu X and Yao J: Systemic inflammatory biomarkers
predict survival of patients treated with tyrosine kinase
inhibitors for metastatic renal cell carcinoma. Cancer Control.
30:107327482311975112023. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Khan AI, Psutka SP, Patil DH, Hong G,
Williams MA, Bilen MA, Sekhar A, Kissick HT, Narayan VM, Joshi SS,
et al: Sarcopenia and systemic inflammation are associated with
decreased survival after cytoreductive nephrectomy for metastatic
renal cell carcinoma. Cancer. 128:2073–2084. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Cheng Y, Kou W and Zhu Y: Preoperative
inflammation-associated blood cell markers in patients with
non-metastatic clear cell renal cell carcinoma: A retrospective
study. Int J Gen Med. 16:3067–3080. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhang Q, Song HF, Ma BL, Zhang ZN, Zhou
CH, Li AL, Liu J, Liang L, Zhu SY and Zhang Q: Pre-operative
prognostic nutritional index as a predictive factor for prognosis
in non-metastatic renal cell carcinoma treated with surgery.
Beijing Da Xue Xue Bao Yi Xue Ban. 55:149–155. 2023.(In Chinese).
PubMed/NCBI
|
|
49
|
Anpalakhan S, Signori A, Cortellini A,
Verzoni E, Giusti R, Aprile G, Ermacora P, Catino A, Pipitone S, Di
Napoli M, et al: Using peripheral immune-inflammatory blood markers
in tumors treated with immune checkpoint inhibitors: An INVIDIa-2
study sub-analysis. iScience. 26:1079702023. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Rebuzzi SE, Signori A, Buti S, Banna GL,
Murianni V, Damassi A, Maruzzo M, Giannarelli D, Tortora G, Galli
L, et al: Validation of the Meet-URO score in patients with
metastatic renal cell carcinoma receiving first-line nivolumab and
ipilimumab in the Italian expanded access program. ESMO Open.
7:1006342022. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Aslan V, Kılıç ACK, Sütcüoğlu O, Eraslan
E, Bayrak A, Öksüzoğlu B, Tahtacı G, Özdemir N, Üner A, Günel N, et
al: Cachexia index in predicting outcomes among patients receiving
immune checkpoint inhibitor treatment for metastatic renal cell
carcinoma. Urol Oncol. 40:494.e1–e10. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ueda K, Suekane S, Kurose H, Ogasawara N,
Hiroshige T, Chikui K, Uemura K, Nakiri M, Nishihara K, Matsuo M
and Igawa T: Absolute lymphocyte count is an independent predictor
of survival in patients with metastatic renal cell carcinoma
treated with nivolumab. Jpn J Clin Oncol. 52:179–186. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Singh N, Baby D, Rajguru JP, Patil PB,
Thakkannavar SS and Pujari VB: Inflammation and cancer. Ann Afr
Med. 18:121–126. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Mierke CT: The fundamental role of
mechanical properties in the progression of cancer disease and
inflammation. Rep Prog Phys. 77:0766022014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Balkwill F: TNF-alpha in promotion and
progression of cancer. Cancer Metastasis Rev. 25:409–416. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Orange ST, Leslie J, Ross M, Mann DA and
Wackerhage H: The exercise IL-6 enigma in cancer. Trends Endocrinol
Metab. 34:749–763. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Hart PC, Rajab IM, Alebraheem M and
Potempa LA: C-reactive protein and cancer-diagnostic and
therapeutic insights. Front Immunol. 11:5958352020. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Carnevale S, Ghasemi S, Rigatelli A and
Jaillon S: The complexity of neutrophils in health and disease:
Focus on cancer. Semin Immunol. 48:1014092020. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Zahorec R: Neutrophil-to-lymphocyte ratio,
past, present and future perspectives. Bratisl Lek Listy.
122:474–488. 2021.PubMed/NCBI
|
|
60
|
Templeton AJ, McNamara MG, Šeruga B,
Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G,
Knox JJ, Tran B, et al: Prognostic role of neutrophil-to-lymphocyte
ratio in solid tumors: A systematic review and meta-analysis. J
Natl Cancer Inst. 106:dju1242014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Shaul ME and Fridlender ZG:
Tumour-associated neutrophils in patients with cancer. Nat Rev Clin
Oncol. 16:601–620. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Masucci MT, Minopoli M and Carriero MV:
Tumor associated neutrophils. Their role in tumorigenesis,
metastasis, prognosis and therapy. Front Oncol. 9:11462019.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Wang B, Gu W, Wan F, Shi G and Ye D:
Prognostic significance of the dynamic changes of systemic
inflammatory response in metastatic renal cell carcinoma. Int Braz
J Urol. 45:89–99. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Hu K, Lou L, Ye J and Zhang S: Prognostic
role of the neutrophil-lymphocyte ratio in renal cell carcinoma: A
meta-analysis. BMJ Open. 5:e0064042015. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Chandrasekaran D, Sundaram S, Maheshkumar
K, Kathiresan N and Padmavathi R: Preoperative
neutrophil-lymphocyte ratio/platelet-lymphocyte ratio: A potential
and economical marker for renal cell carcinoma. J Cancer Res Ther.
18:1635–1639. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Ohno Y, Nakashima J, Ohori M, Gondo T,
Hatano T and Tachibana M: Followup of neutrophil-to-lymphocyte
ratio and recurrence of clear cell renal cell carcinoma. J Urol.
187:411–417. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Ito K, Masunaga A, Tanaka N, Mizuno R,
Shirotake S, Yasumizu Y, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, et
al: Impact of inflammatory marker levels one month after the
first-line targeted therapy initiation on progression-free survival
prediction in patients with metastatic clear cell renal cell
carcinoma. Jpn J Clin Oncol. 49:69–76. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Chen X, Meng F and Jiang R:
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for
patients with metastatic renal cell carcinoma treated with immune
checkpoint inhibitors: A systematic review and meta-analysis. Front
Oncol. 11:7469762021. View Article : Google Scholar : PubMed/NCBI
|
